What is Zacks Research’s Forecast for COO Q2 Earnings?

The Cooper Companies, Inc. (NASDAQ:COO) – Analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Cooper Companies in a research report issued to clients and investors on Thursday, March 26th. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $1.09 per share for the quarter, up from their prior forecast of $1.07. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.22 EPS, FY2026 earnings at $4.58 EPS, Q1 2027 earnings at $1.16 EPS, Q2 2027 earnings at $1.18 EPS, Q4 2027 earnings at $1.29 EPS, FY2027 earnings at $4.89 EPS and FY2028 earnings at $5.34 EPS.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the company earned $0.92 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS.

A number of other equities analysts have also recently issued reports on COO. Robert W. Baird upped their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Mizuho set a $100.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a research note on Friday, December 5th. William Blair raised shares of Cooper Companies to a “strong-buy” rating in a report on Friday, January 30th. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Stifel Nicolaus set a $95.00 price target on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $90.79.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $69.77 on Friday. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $89.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The business has a fifty day moving average price of $78.82 and a 200-day moving average price of $76.11. The company has a market capitalization of $13.61 billion, a PE ratio of 34.54, a PEG ratio of 1.84 and a beta of 1.02.

Hedge Funds Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently bought and sold shares of COO. Root Financial Partners LLC grew its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares during the period. Bell Investment Advisors Inc lifted its position in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in Cooper Companies in the second quarter worth approximately $36,000. True Wealth Design LLC boosted its holdings in Cooper Companies by 484.8% in the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock worth $38,000 after purchasing an additional 383 shares during the last quarter. Finally, Cromwell Holdings LLC grew its position in Cooper Companies by 128.8% in the 4th quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock worth $40,000 after purchasing an additional 273 shares during the period. Institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised several quarterly and full‑year EPS forecasts for Cooper (FY2026–FY2028 and multiple quarters), signaling improved analyst expectations for margin and earnings momentum — a catalyst that can support the stock over time. Zacks boosts COO estimates (MarketBeat summary)
• Neutral Sentiment: A Zacks feature highlights Cooper’s premium contact‑lens momentum and margin gains as reasons to consider adding the stock, which underpins a constructive medium‑term view but notes mixed near‑term signals. Reasons to Add Cooper Companies Stock to Your Portfolio Now
• Negative Sentiment: The same analyst coverage warns of Asia market softness and broader geopolitical risks that could blunt top‑line growth for Cooper’s international lens business — a near‑term headwind that likely contributed to today’s selling. Risks: Asia weakness & geopolitical concerns (Zacks)

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.